Rabbit Polyclonal FCGRT/FCRN antibody. Extracellular domain. Suitable for WB and reacts with Mouse, Human samples. Cited in 6 publications. Immunogen corresponding to Recombinant Fragment Protein within Human FCGRT aa 1-300.
pH: 7.4
Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol (glycerin, glycerine), 49% PBS
WB | IHC-P | ICC/IF | |
---|---|---|---|
Human | Tested | Not recommended | Not recommended |
Mouse | Tested | Not recommended | Not recommended |
Cynomolgus monkey | Predicted | Not recommended | Not recommended |
Species | Dilution info | Notes |
---|---|---|
Species Mouse | Dilution info 1/500 - 1/2000 | Notes - |
Species Human | Dilution info 1/500 - 1/2000 | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Cynomolgus monkey | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human, Mouse, Cynomolgus monkey | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human, Mouse, Cynomolgus monkey | Dilution info - | Notes - |
Select an associated product type
Cell surface receptor that transfers passive humoral immunity from the mother to the newborn. Binds to the Fc region of monomeric immunoglobulin gamma and mediates its selective uptake from milk (PubMed:10933786, PubMed:7964511). IgG in the milk is bound at the apical surface of the intestinal epithelium. The resultant FcRn-IgG complexes are transcytosed across the intestinal epithelium and IgG is released from FcRn into blood or tissue fluids. Throughout life, contributes to effective humoral immunity by recycling IgG and extending its half-life in the circulation. Mechanistically, monomeric IgG binding to FcRn in acidic endosomes of endothelial and hematopoietic cells recycles IgG to the cell surface where it is released into the circulation (PubMed:10998088). In addition of IgG, regulates homeostasis of the other most abundant circulating protein albumin/ALB (PubMed:24469444, PubMed:28330995). (Microbial infection) Acts as an uncoating receptor for a panel of echoviruses including Echovirus 5, 6, 7, 9, 11, 13, 25 and 29.
FCRN, FCGRT, IgG receptor FcRn large subunit p51, FcRn, IgG Fc fragment receptor transporter alpha chain, Neonatal Fc receptor
Rabbit Polyclonal FCGRT/FCRN antibody. Extracellular domain. Suitable for WB and reacts with Mouse, Human samples. Cited in 6 publications. Immunogen corresponding to Recombinant Fragment Protein within Human FCGRT aa 1-300.
pH: 7.4
Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol (glycerin, glycerine), 49% PBS
>95%
The protein FCGRT also known as FCRN or FcRn has a significant role in the immune system by binding to the Fc region of immunoglobulin G (IgG). This binding prolongs the half-life of IgG by preventing its lysosomal degradation. The molecular mass of the FCGRT protein is roughly 52 kDa. It is prominently expressed in epithelial and endothelial cells across several tissues including the placenta and liver ensuring IgG stability in circulation.
FCGRT/FCRN is involved in the transportation and recycling of IgG antibodies. It forms a complex with beta-2 microglobulin that contributes to its function. This complex allows IgG antibodies to traverse cellular barriers such as epithelial cells without being digested. This protein is important in maintaining humoral immunity by regulating IgG levels in the bloodstream and similar processes can be observed in mouse FCRN and cynomolgus monkey milk indicating a conserved mechanism across species.
FCGRT/FCRN plays a part in the neonatal Fc receptor pathway. This pathway influences IgG homeostasis and impacts antigen presentation to T cells. By doing so it affects immune surveillance and immune tolerance mechanisms. The pathway involves interactions with related proteins such as albumin which also binds to FCRN for extending its half-life in serum.
Disruptions in FCGRT/FCRN functionality relate to autoimmune conditions and inflammatory diseases. Conditions such as lupus and myasthenia gravis show altered IgG recycling or transportation implicating FCRN in their pathology. Accordingly researchers have explored FCRN inhibitors as potential therapeutic interventions. These inhibitors aim to modulate the interaction between FCRN and IgG therefore impacting the disease progression linked to these disorders.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
All lanes: Western blot - Anti-FCGRT/FCRN antibody - Extracellular domain (ab193148) at 2 µg
Lane 1: HepG2 whole cell lysate
Lane 2: Mouse liver tissue
Lane 3: Mouse spleen tissue
Lane 4: A549 whole cell lysate
All lanes: Goat polyclonal to rabbit IgG at 1/1000 dilution
Predicted band size: 40 kDa
Observed band size: 40 kDa
All lanes: Western blot - Anti-FCGRT/FCRN antibody - Extracellular domain (ab193148) at 5.3 µg/mL
Lane 1: Mouse liver tissue lysate
Lane 2: Mouse kidney tissue lysate
All lanes: Polyclonal goat anti-rabbit IgG at 1/10000 dilution
Predicted band size: 40 kDa
Observed band size: 39 kDa
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com